A Prospective, Observational Study to Evaluate Changes in Non-Motor Symptoms and Other Clinical Outcome Assessments of Parkinson's Disease Patients Treated With XADAGO (Safinamide)Tablets
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms PRO-Go
- Sponsors Supernus Pharmaceuticals; US WorldMeds
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 21 Feb 2020 Status changed from recruiting to completed.
- 10 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020.